These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11246601)

  • 1. Yasmin--a new oral contraceptive, a new progestogen: the reasons why.
    Mansour D
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():9-16. PubMed ID: 11246601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yasmin: the reason why.
    Thorneycroft IH
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
    Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
    Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
    Mansour D
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido.
    Oranratanaphan S; Taneepanichskul S
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S17-22. PubMed ID: 17726807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is [symbol: see text] Yasmin a "truly different" pill?
    Drug Ther Bull; 2002 Aug; 40(8):57-9. PubMed ID: 12216337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers.
    Blode H; Wuttke W; Loock W; Röll G; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):256-64. PubMed ID: 11245553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H; Foidart JM; Heithecker R
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosexual well-being in women using oral contraceptives containing drospirenone.
    Nappi RE; Albani F; Tonani S; Santamaria V; Pisani C; Terreno E; Martini E; Polatti F
    Funct Neurol; 2009; 24(2):71-5. PubMed ID: 19775533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraception: trends over time.
    Yuzpe AA
    J Reprod Med; 2002 Nov; 47(11 Suppl):967-73. PubMed ID: 12497670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.